Journal of Clinical PracticeJournal of Clinical Practice2220-30952618-8627Eco-Vector819510.17816/clinpract2147-53Research ArticleIMMUNOTROPIC AGENTS IN COMPLEX TREATMENT OF CHILDREN WITH INTERMITTENT ALLERGIC RHINITIS AND RECURRENT RESPIRATORY INFECTIONSChigaevaE V-GrankinaN E-1503201121475316032018Copyright © 2011, Chigaeva E.V., Grankina N.E.2011The purpose of the research was to develop a prescribing of immunomodulators Imudon, Viferon, Superlymph in the complex treatment of frequently ill children (FIC) with a frequency of ARI 6 or more times a year, foci of chronic infection in oro and nasopharynx, and intermittent (seasonal) AR mild or moderate severity (SAR). Methods: 120 FIC from 5 to 7 years old (56 boys and 64 girls) were followedup during 2 years. Investigation revealed pollen and household allergens predomination in the spectrum of causesignificant allergens. Microbial landscape of chronic infection foci in the oro and nasopharynx was characterized by a predominance of Staphylococcus aureus in 71,2%, Candida albicans in 28,8%, Streptococcus haemolyticus in 50% of patients. In 67.4% of patients microbial associations of 2 and 3 pathogens predominated. Immune system abnormalities were characterized by reduction in T cells, the level of serum IgA in 62.5%, gammaIFN – in 80%, alphainterferon – a 60% increase in serum IgG – at 62,5%, TNFα – 80,0%, and IgE – in 100% of the children. Supplementation of Imudon, Superlymph and Viferon as a component of complex treatment of this category of children reduces the mucous contamination with active forms of Candida albicans by 24 times, with bacterial flora ( Staphylococcus aureus, Streptococcus spp. ) in 2 3,4 times, reduces inflammation of the mucous membranes of oro and nasopharynx, adenoid hypertrophy, reduces the frequency of ARI in 1,9, 2,5 and 3,1 times respectively. In 16,6% of FIC with SAR who did not receive immunomodulators in complex treatment, persistent AR developed in a year of observation. Cases of persistent AR in groups of children receiving Superlymph or Viferon were not revealed.frequently ill childrenimmunological parametersAR intermittent mild and moderate severity (SAR)immune drugs (ViferonImudonSuperlymph)часто болеющие детииммунологические показателиинтермиттирующий аллергический ринит легкой и средней степени тяжестииммунотропные препаратывиферонимудонсуперлимф[Коровина Н.А., Заплатников А.Л., Чебуркин А.В., Захарова И.Н. Часто и длительно болеющие дети: современные возможности иммунореабилитации: Руководство для врачей. М.: Контимед, 2001. 68 с.][Маркова Т.П., Чувиров Д.Г. Применение топических иммуномодуляторов в группе длительно и часто болеющих детей / В кн. Иммунокоррекция в педиатрии под ред. М.В. Костинова. М.,2001. С.91-99.][Пискунов С.З., Пискунов Г.З. Клиническая ринология. М.: Миклош, 2002.][Ильина Н.И. Аллергический ринит // Consilium Medicum. 2000. Т. 1, № 8. С. 338-344.][Schröder N.W., Crother T.R., Naiki Y. et al. Innate immune responses during respiratory tract infection with a bacterial pathogen induce allergic airway sensitization // J. Allergy Clin. Immunol. 2008. Vol. 122 (3). Р. 595-602.][Аллахвердиева Л.И. Некоторые аспекты патогенеза и лечения респираторной аллергопатологии у детей и подростков // Иммунология. 2006. № 1. С. 34-40.][Martinez F.D. Development of wheezing disorders and asthma in preschool children // Pediatrics. 2002. Vol. 109. Р. 362-367.][Zakrzewska A., Kobos J., G\rski P. The implications of nasal associated lymphoid tissue in development of respiratory allergic diseases in children // Med. Wieku Rozwoj. 2007. Vol. 11 (2 Pt 1). Р. 129-134.][Holgate S.T., Broide D. New targets for allergic rhinitis – a disease of civilization // Nat. Rev. Drug Discov. 2003. 2 (11). P. 902-914.][Гущина Я.С., Касснер Л.Н., Маркелова Е.В., Ицкович А.И. Уровень провоспалительных цитокинов в оценке активности воспалительного процесса при бронхолегочной патологии у детей // Цитокины и воспаление. 2006. Т. 5, № 4. С. 36-38.][Маркова Т.П. Иммунотропные препараты в педиатрии // Доктор РУ. 2008. № 1. С.48-52.]